WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), has filed its quarterly report with the Securities and Exchange Commission yesterday, November 14th, in a timely fashion.
The Company reported that it had approximately $10.879M in cash and cash equivalents, and approximately $321,900 in prepaid expenses as of September 30, 2011, the end of the reporting quarter. The shareholder equity stood at approximately $11.386M. In comparison, the Company had approximately $9.224M in cash and cash equivalents, approximately $332,300 in prepaid expenses and other cash equivalent assets, and $10.171M in shareholder equity as of the financial year ended June 30, 2011. The Company spent approximately $692,000 in Research and Development expenses (R&D) and approximately $448,700 in General and Administrative expenses (G&A) in the reported quarter. The Company’s rate of cash expenditure was in line with the Company’s budgeted targets.
